Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: Clin Cancer Investig J. 2014;3(1):72–79. doi: 10.4103/2278-0513.125802

Table 3.

AUC (95% CI) estimates for individual biomarkers and their combinations to distinguish between localized versus metastatic CaP

Markers AUC (95%)
PSA 0.963 (0.937–0.990)
IL-8 0.663 (0.566–0.761)
TNF-α 0.992 (0.983–1.000)
sTNFR1 0.865 (0.788–0.942)
TNF-α and sTNFR1 0.993 (0.985–1.000)
TNF-α and PSA 0.999 (0.998–1.000)
TNF-α and IL-8 0.992 (0.983–1.000)
sTNFR1 and PSA 0.971 (0.950–0.993)
sTNFR1 and IL-8 0.870 (0.801–0.938)
PSA and IL-8 0.964 (0.938–0.990)
TNF-α and sTNFR1 and PSA 0.999 (0.998–1.000)
TNF-α and sTNFR1 and IL-8 0.994 (0.985–1.000)
TNF-α and PSA and IL-8 0.999 (0.998–1.000)
sTNFR1 and PSA and IL-8 0.975 (0.957–0.994)
TNF-α and sTNFR1 and PSA and IL-8 0.999 (0.998–1.000)

AUC: Area under the receiver operating characteristic curve, ROC: Receiver operating characteristic, CI: Confidence interval, CaP: Prostate cancer, PSA: Prostate-specific antigen, IL: Interleukin, TNF: Tumor necrosis factor-α, sTNFR1: Soluble tumor necrosis factor-α receptors 1